Trials / Terminated
TerminatedNCT02753218
A Phase I Study With LEO 32731 and Midazolam in Healthy Male Subjects
LEO 32731 - A Phase I Drug-Drug Interaction Study With LEO 32731 and Midazolam in Healthy Male Subjects
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- LEO Pharma · Industry
- Sex
- Male
- Age
- 18 Years – 59 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to investigate the effects of multiple oral doses of LEO 32731 on the pharmacokinetics of a single oral dose of the cytochrome P450 3A substrate midazolam in healthy male subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Midazolam | |
| DRUG | LEO 32731 |
Timeline
- Start date
- 2016-04-01
- Primary completion
- 2016-05-01
- Completion
- 2016-05-01
- First posted
- 2016-04-27
- Last updated
- 2017-05-03
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT02753218. Inclusion in this directory is not an endorsement.